Grifois, S.A. (GRFS) Stock Price

GRFSStock

$7.64−13.21%52W

Market Cap$5.20B

P/E14.89x

PEG Ratio0.19

Div yield1.92%

Beta0.82

GRFS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-2.09%

Price vs S&P 500 (4W)7.50%

PEG Ratio0.19

VGM Score63.19

P/E Ratio (Annual)14.89x

Indicated Dividend Yield (Annual)1.92%

P/CF (Annual)5.72x

Book Value / Share (Quarterly)$9.15

P/TBV (Annual)2.58x

Indicated Dividend (Annual)$0.26

Revenue Growth (3Y)7.46%

Cash Flow / Share (Quarterly)$1.06

Payout Ratio (TTM)56.83%

Price vs S&P 500 (YTD)-15.82%

Gross Margin (TTM)36.98%

Net Profit Margin (TTM)6.09%

EPS (TTM)$0.75

10-Day Avg Trading Volume1.59M

EPS Excl Extra (TTM)$0.75

Revenue Growth (5Y)7.10%

EPS (Annual)$0.66

Dividend / Share (Annual)$0.21

ROI (Annual)2.70%

Gross Margin (Annual)38.00%

Net Profit Margin (5Y Avg)3.14%

Cash / Share (Quarterly)$1.18

P/E Basic Excl Extra (TTM)13.24x

Revenue Growth QoQ (YoY)-0.91%

EPS Growth (5Y)-8.12%

P/E Normalized (Annual)14.89x

ROA (Last FY)2.04%

Revenue Growth TTM (YoY)-0.33%

EBITD / Share (TTM)$2.70

ROE (5Y Avg)3.64%

Operating Margin (TTM)16.20%

Cash Flow / Share (Annual)$1.03

P/B Ratio1.08x

P/B Ratio (Quarterly)0.99x

Net Income / Employee (Annual)$17,848

EV / Revenue (TTM)1.92x

Net Interest Coverage (TTM)2.22x

ROA (TTM)2.27%

EPS Growth QoQ (YoY)-5.00%

EV / EBITDA (TTM)8.68x

EPS Incl Extra (Annual)$0.66

Current Ratio (Annual)2.51x

Quick Ratio (Quarterly)0.81x

3-Month Avg Trading Volume1.54M

52-Week Price Return-13.21%

EV / Free Cash Flow (Annual)22.88x

P/E Incl Extra (TTM)13.24x

Revenue / Employee (TTM)$329,793

Tangible BV / Share (Quarterly)$4.53

P/S Ratio (Annual)0.80x

Asset Turnover (Annual)0.38x

52-Week High$13.39

Operating Margin (5Y Avg)14.07%

EPS Excl Extra (Annual)$0.66

CapEx CAGR (5Y)7.44%

Tangible BV CAGR (5Y)-6.46%

26-Week Price Return7.82%

Quick Ratio (Annual)0.88x

13-Week Price Return8.11%

Total Debt / Equity (Annual)1.83x

Current Ratio (Quarterly)2.37x

Enterprise Value$16.02B

Revenue / Share Growth (5Y)7.25%

Asset Turnover (TTM)0.37x

Book Value / Share Growth (5Y)0.75%

Revenue / Employee (Annual)$334,396

Inventory Turnover (Annual)1.36x

Pretax Margin (Annual)8.17%

Cash / Share (Annual)$1.38

3-Month Return Std Dev27.50%

Gross Margin (5Y Avg)38.23%

Net Income / Employee (TTM)$20,093

EBITDA CAGR (5Y)4.77%

EBITDA Interim CAGR (5Y)8.82%

ROE (Last FY)7.63%

Net Interest Coverage (Annual)2.37x

EPS Basic Excl Extra (Annual)$0.66

P/FCF (TTM)9.30x

Receivables Turnover (TTM)9.15x

EV / Free Cash Flow (TTM)22.18x

Total Debt / Equity (Quarterly)1.59x

EPS Incl Extra (TTM)$0.75

Receivables Turnover (Annual)10.20x

ROI (TTM)3.09%

Dividend Growth Rate (5Y)2.54%

P/S Ratio (TTM)0.81x

Pretax Margin (5Y Avg)6.16%

Revenue / Share (Annual)$12.41

Tangible BV / Share (Annual)$4.19

Forward P/E9.19x

Price vs S&P 500 (52W)-28.75%

P/E Ratio (TTM)13.24x

EPS Growth TTM (YoY)52.73%

Year-to-Date Return-4.86%

5-Day Price Return1.60%

EPS Normalized (Annual)$0.66

ROA (5Y Avg)1.00%

Net Profit Margin (Annual)5.34%

Month-to-Date Return6.60%

EBITD / Share (Annual)$2.33

EPS Growth (3Y)24.46%

Operating Margin (Annual)16.48%

LT Debt / Equity (Annual)1.55x

P/CF (TTM)5.48x

ROI (5Y Avg)1.31%

P/E Excl Extra (TTM)13.24x

LT Debt / Equity (Quarterly)1.34x

EPS Basic Excl Extra (TTM)$0.75

P/TBV (Quarterly)1.99x

Payout Ratio (Annual)31.84%

P/B Ratio (Annual)1.25x

Dividend / Share (TTM)$0.21

Inventory Turnover (TTM)1.37x

Pretax Margin (TTM)9.00%

Book Value / Share (Annual)$8.69

Price vs S&P 500 (13W)5.43%

Net Margin Growth (5Y)-14.34%

Dividend Yield (TTM)2.14%

Beta0.82x

P/FCF (Annual)9.60x

Revenue / Share (TTM)$8.74

ROE (TTM)8.43%

52-Week Low$9.47

vGradeB

gGradeC

mGradeB

vgmGradeB

GRFS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 28, 2026	$0.31	$0.19	-40.06%(-$0.12)
Q2 2025	Jul 28, 2025	$0.31	$0.25	-19.19%(-$0.06)

GRFS Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.81

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
GRFSGrifois, S.A.	B	C	B	0.8x	-0.3%	37.0%	-8.1%	$7.64
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Grifois, S.A.

Grifols is a global specialty plasma therapeutics company that develops, manufactures, and distributes protein-based medicines for immunological deficiencies, hemophilia, and other chronic and life-threatening conditions. The company's portfolio serves both diagnostic and therapeutic applications across rare and inherited diseases with significant unmet medical needs. Grifols generates the majority of its revenue from the United States market.